Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity

References

• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A Predictive Model for Aggressive non-Hodgkin's Lymphoma. N Eng J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Steele J G, Savolainen T A, Dalton B A, Smith L, Smith G L. Adhesion to laminin and expression of laminin in clonally elated transformed and control sublines from an alveolar epithelial cell strain. Cancer Res 1990; 50: 3383–3389
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Shoda J, Asano T, et al. Expression of cyclooxygenase – 2 in the subserosal layer correlates with post surgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002; 98: 427–434
   PubMed Web of Science ®Google Scholar
• Ranuncolo S M, Matos E, Loria D, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 2002; 94: 1483–1491
   PubMed Web of Science ®Google Scholar
• Ruiter D, Bigenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002; 3: 35–43
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Fanelli M, et al. Expression of tenascin is related to histologic malignancy and angiogenesis in B cell non-Hodgkin's lymphomas. Leuk Lymphoma 1996; 22: 473–481
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Demmacco F. Angiogenesis spectrum in the stroma of B cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56: 45–53
   PubMed Web of Science ®Google Scholar
• Mackie E J. Molecules in focus: Tenascin-C. Int J Biochem Cell Biol 1997; 29: 1133–1137
   PubMed Web of Science ®Google Scholar
• Canfield A E, Schor A M. Evidence that tenascin and thrombospondin – l modulate sprouting of endothelial cells. J Cell Sci 1995; 108: 797–809
   PubMed Web of Science ®Google Scholar
• Forsberg E, Hirsch E, Frohlich L, et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 1996; 93: 6594–6599
   PubMed Web of Science ®Google Scholar
• Kostianovsky M, Greco M A, Cangiarella J, Zagzag D. Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions. Ultrastruct Pathol 1997; 21: 537–544
   PubMed Web of Science ®Google Scholar
• Bigner D D, Brown M T, Friedman A H, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant glioma: Phase I trial of results. J Clin Oncol 1998; 16: 2202–2212
   PubMed Web of Science ®Google Scholar
• McLendon R E, Wikstrand C J, Matthews M R, Al-Baradei R, Bigner S H, Bigner D D. Glioma associated antigen expression in oligodendroglial neoplasms: tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000; 48: 1103–1110
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M, et al. Bone Marrow Neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064–3073
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B cell NHL. Int J Cancer 2000; 85: 171–175
   PubMed Web of Science ®Google Scholar
• Pruneri G, Ponzoni M, Ferreri A J, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118: 817–820
   PubMed Web of Science ®Google Scholar
• Bosari S, Lee A KC, Delellis R A, Wiley B D, Heatley G J, Silverman M L. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755–761
   PubMed Web of Science ®Google Scholar
• Guinebretiere J M, LeMonique G, Bahi J, Contesso G. Angiogenesis at risk in breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994; 86: 635–636
   PubMed Web of Science ®Google Scholar
• Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2, and CA IX in NHL. Histopathology 2002; 40: 253–260
   PubMed Web of Science ®Google Scholar
• Zagzag D, Friedlander D R, Dosik J, et al. Tenascin C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996; 56: 182–189
   PubMed Web of Science ®Google Scholar
• Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of Tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996; 69: 445–447
   PubMed Web of Science ®Google Scholar
• Broll R, Meyer S, Nuber M, Bruch H P. Expression of Tenascin in tumors of the esophagus, small intestine and colorectum. Gen Diagn Pathol 1995; 141: 111–119
   PubMedGoogle Scholar
• Kusagawa H, Onoda K, Namikawa S, et al. Expression and degradation of Tenascin C in human lung cancers. Br J Cancer 1998; 77: 98–102
   PubMed Web of Science ®Google Scholar
• Fine H, Loeffler J S, Kyritsis A, et al. Phase II trial of anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. Proceedings of ASCO 1997; 16: #1372
   Google Scholar
• Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600–608
   PubMed Web of Science ®Google Scholar
• Pazgal I, Zimra Y, Tzabar C, et al. Expression of basic fibroblast growth factor in associated with poor outcome in NHL. Br J. Cancer 2002; 86: 1770–1775
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum VEGF concentration is associated with poor outcome in NHL. Blood 1997; 90: 3167–3172
   PubMed Web of Science ®Google Scholar
• Nishi J, Arimura K, Utsunomiya A, et al. Expression of VEGF in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999; 104: 482–485
   PubMed Web of Science ®Google Scholar
• Sezer O, Niemoller K, Kaufmann O, Eucker J, Jacob C, Zavrski I. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001; 66: 238–244
   PubMed Web of Science ®Google Scholar